m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00923)
Name
8-chloro-quinoline-3-carbonitrile
Synonyms
CHEMBL436817; Cyanoquinoline, 11; SCHEMBL6071997; BDBM21898; CHEBI:94979; BRD-K00088062-001-01-3; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1H-imidazole-5-ylmethyl)amino]-8-chloro-3-quinolinecarbonitrile
    Click to Show/Hide
Status
Investigative
Structure
Formula
C20H13Cl2FN6
InChI
1S/C20H13Cl2FN6/c21-16-4-12(1-2-18(16)23)29-19-11(6-24)7-27-20-15(19)3-13(5-17(20)22)26-9-14-8-25-10-28-14/h1-5,7-8,10,26H,9H2,(H,25,28)(H,27,29)
InChIKey
ONXROKMQGCSOMG-UHFFFAOYSA-N
PubChem CID
17759555
TTD Drug ID
D03MUZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-3 (MMP-3)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for 8-chloro-quinoline-3-carbonitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-chloro-quinoline-3-carbonitrile through regulating the expression of Matrix metalloproteinase-3 (MMP-3). [1], [2]
References
Ref 1 METTL3 Promotes Activation and Inflammation of FLSs Through the NF-KappaB Signaling Pathway in Rheumatoid Arthritis. Front Med (Lausanne). 2021 Jul 6;8:607585. doi: 10.3389/fmed.2021.607585. eCollection 2021.
Ref 2 Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1970-6. doi: 10.1016/j.bmcl.2009.02.044. Epub 2009 Feb 14.